make use of colchicine (or other low-toxicity drugs) to increase viral and antigen distribution and in the epithelium and lamina propria. Second, they may develop recombinant vaccinia viruses using genes that target antigen budding from the basolateral surface, such as the M protein gene of VSV [46,47]. Third, they may select viruses that are preferentially released from the basolateral surface, such as VSV, for use as vaccine vectors. References 1. Kresina TF, Mathieson B (1999) Human immunodeficiency virus type 1 infection, mucosal immunity, and pathogenesis and extramural research programs at the National Institutes of Health. J Infect Dis 179 Suppl 3: S392–396. 2. Belyakov IM, Berzofsky JA (2004) Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity 20: 247–253. 3. Bomsel M, Tudor D, Drillet AS, Alfsen A, Ganor Y, et al. (2011) Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 34: 269–280. 4. Mazzoli S, Trabattoni D, Lo Caputo S, Piconi S, Ble C, et al. (1997) HIV- specific mucosal and cellular immunity in HIV-seronegative partners of HIV- seropositive individuals. Nat Med 3: 1250–1257. 5. Beyrer C, Artenstein AW, Rugpao S, Stephens H, VanCott TC, et al. (1999) Epidemiologic and biologic characterization of a cohort of human immunode- ficiency virus type 1 highly exposed, persistently seronegative female sex workers in northern Thailand. Chiang Mai HEPS Working Group. J Infect Dis 179: 59–67. 6. Kaul R, Trabattoni D, Bwayo JJ, Arienti D, Zagliani A, et al. (1999) HIV-1- specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. Aids 13: 23–29. 7. Kaul R, Plummer F, Clerici M, Bomsel M, Lopalco L, et al. (2001) Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection. Aids 15: 431–432. 8. Miyazawa M, Lopalco L, Mazzotta F, Lo Caputo S, Veas F, et al. (2009) The ‘immunologic advantage’ of HIV-exposed seronegative individuals. Aids 23: 161–175. 9. Genesca M, Skinner PJ, Bost KM, Lu D, Wang Y, et al. (2008) Protective attenuated lentivirus immunization induces SIV-specific T cells in the genital tract of rhesus monkeys. Mucosal Immunol 1: 219–228. 10. Ahlers JD, Belyakov IM (2009) Strategies for optimizing targeting and delivery of mucosal HIV vaccines. Eur J Immunol 39: 2657–2669. 11. Cripps AW, Kyd JM, Foxwell AR (2001) Vaccines and mucosal immunisation. Vaccine 19: 2513–2515. 12. Eriksson K, Holmgren J (2002) Recent advances in mucosal vaccines and adjuvants. Curr Opin Immunol 14: 666–672. 13. Holmgren J, Czerkinsky C (2005) Mucosal immunity and vaccines. Nat Med 11: S45–53. 14. Gherardi MM, Esteban M (2005) Recombinant poxviruses as mucosal vaccine vectors. J Gen Virol 86: 2925–2936. 15. Moss B (1992) Poxvirus expression vectors. Curr Top Microbiol Immunol 158: 25–38. 16. Mackett M, Smith GL, Moss B (1992) Vaccinia virus: a selectable eukaryotic cloning and expression vector. 1982. Biotechnology 24: 495–499. 17. Hu SL, Kosowski SG, Dalrymple JM (1986) Expression of AIDS virus envelope gene in recombinant vaccinia viruses. Nature 320: 537–540. 18. Lane JM, Ruben FL, Neff JM, Millar JD (1969) Complications of smallpox vaccination, 1968. N Engl J Med 281: 1201–1208. 19. Redfield RR, Wright DC, James WD, Jones TS, Brown C, et al. (1987) Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 316: 673–676. 20. Zhu W, Fang Q, Zhuang K, Wang H, Yu W, et al. (2007) The attenuation of vaccinia Tian Tan strain by the removal of the viral M1L-K2L genes. J Virol Methods 144: 17–26. 21. Yu W, Fang Q, Zhu W, Wang H, Tien P, et al. (2010) One time intranasal vaccination with a modified vaccinia Tiantan strain MVTT(ZCI) protects animals against pathogenic viral challenge. Vaccine 28: 2088–2096. 22. Huang X, Lu B, Yu W, Fang Q, Liu L, et al. (2009) A novel replication- competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination. PLoS One 4: e4180. 23. Sinopharm website. Available: http://www.sinopharm.com/398-1118-22744. aspx. Accessed 2009 Jan 21. 24. Yin L, Zhang Y, Qian HZ, Rui B, Zhang L, et al. (2008) Willingness of Chinese injection drug users to participate in HIV vaccine trials. Vaccine 26: 762–768. 25. Sinn PL, Williams G, Vongpunsawad S, Cattaneo R, McCray PB, Jr. (2002) Measles virus preferentially transduces the basolateral surface of well- differentiated human airway epithelia. J Virol 76: 2403–2409. Unpolarized Release Enhances Mucosal Responses Acknowledgments Sincere thanks to Drs. Zhiwei Chen and Ke Zhuang for providing rVTT- gagpol vaccinia virus and Professor Bing Yan for providing polyclonal anti- p24 antibody, and HRP-mouse anti-p24 antibody. Author Contributions Conceived and designed the experiments: YZ JY HY. Performed the experiments: YZ JY RB Y. Chen DZ BH MZ FL QL YY CH YS YL Y. Cao. Analyzed the data: YZ JY HY. Contributed reagents/materials/ analysis tools: YZ JY Y. Chen DZ MZ FL. Wrote the paper: YZ. 26. Cordo SM, Cesio y Acuna M, Candurra (2005) Polarized entry and release of Junin virus, a New World arenavirus. J Gen Virol 86: 1475–1479. 27. Compans RW (1995) Virus entry and release in polarized epithelial cells. Curr Top Microbiol Immunol 202: 209–219. 28. Peacock JW, Nordone SK, Jackson SS, Liao HX, Letvin NL, et al. (2004) Gender differences in human immunodeficiency virus type 1-specific CD8 responses in the reproductive tract and colon following nasal peptide priming and modified vaccinia virus Ankara boosting. J Virol 78: 13163–13172. 29. Takao SI, Kiyotani K, Sakaguchi T, Fujii Y, Seno M, et al. (1997) Protection of mice from respiratory Sendai virus infections by recombinant vaccinia viruses. J Virol 71: 832–838. 30. Xiong Z, Ding H, Li C, Tian Y, Xu Z (2000) Effect of decalcification on immunohistochemical staining of osseous and soft tissue. Chinese Journal of Diagnostic Pathology 7: 45–47. 31. Frey A, Meckelein B, Externest D, Schmidt MA (2000) A stable and highly sensitive 3,39,5,59-tetramethylbenzidine-based substrate reagent for enzyme- linked immunosorbent assays. J Immunol Methods 233: 47–56. 32. Vogel U, Sandvig K, van Deurs B (1998) Expression of caveolin-1 and polarized formation of invaginated caveolae in Caco-2 and MDCK II cells. J Cell Sci 111 (Pt 6): 825–832. 33. Ma JK, Hikmat BY, Wycoff K, Vine ND, Chargelegue D, et al. (1998) Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans. Nat Med 4: 601–606. 34. Dai K, Liu Y, Liu M, Xu J, Huang W, et al. (2008) Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes. Vaccine 26: 5062–5071. 35. Mostov K, Su T, ter Beest M (2003) Polarized epithelial membrane traffic: conservation and plasticity. Nature Cell Biology 5: 287–293. 36. Kreitzer G, Schmoranzer J, Low SH, Li X, Gan Y, et al. (2003) Three- dimensional analysis of post-Golgi carrier exocytosis in epithelial cells. Nat Cell Biol 5: 126–136. 37. Huang X, Liu L, Ren L, Qiu C, Wan Y, et al. (2007) Mucosal priming with replicative Tiantan vaccinia and systemic boosting with DNA vaccine raised strong mucosal and systemic HIV-specific immune responses. Vaccine 25: 8874–8884. 38. Vermeer PD, McHugh J, Rokhlina T, Vermeer DW, Zabner J, et al. (2007) Vaccinia virus entry, exit, and interaction with differentiated human airway epithelia. J Virol 81: 9891–9899. 39. Huang YT, Miller CJ, Wong V, Fujioka H, Nedrud JG, et al. (1999) Replication and budding of simian immunodeficiency virus in polarized epithelial cells. Virology 257: 24–34. 40. Owens RJ, Dubay JW, Hunter E, Compans RW (1991) Human immunode- ficiency virus envelope protein determines the site of virus release in polarized epithelial cells. Proc Natl Acad Sci U S A 88: 3987–3991. 41. Ramirez JC, Finke D, Esteban M, Kraehenbuhl JP, Acha-Orbea H (2003) Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration. Arch Virol 148: 827–839. 42. Fuller S, von Bonsdorff CH, Simons K (1984) Vesicular stomatitis virus infects and matures only through the basolateral surface of the polarized epithelial cell line, MDCK. Cell 38: 65–77. 43. Cornish TE, Stallknecht DE, Brown CC, Seal BS, Howerth EW (2001) Pathogenesis of experimental vesicular stomatitis virus (New Jersey serotype) infection in the deer mouse (Peromyscus maniculatus). Vet Pathol 38: 396–406. 44. Mizumoto N, Gao J, Matsushima H, Ogawa Y, Tanaka H, et al. (2005) Discovery of novel immunostimulants by dendritic-cell-based functional screening. Blood 106: 3082–3089. 45. Mee CJ, Harris HJ, Farquhar MJ, Wilson G, Reynolds G, et al. (2009) Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. J Virol 83: 6211–6221. 46. Bergmann JE, Fusco PJ (1988) The M protein of vesicular stomatitis virus associates specifically with the basolateral membranes of polarized epithelial cells independently of the G protein. J Cell Biol 107: 1707–1715. 47. Zimmer G, Zimmer KP, Trotz I, Herrler G (2002) Vesicular stomatitis virus glycoprotein does not determine the site of virus release in polarized epithelial cells. J Virol 76: 4103–4107. PLoS ONE | www.plosone.org 13 September 2011 | Volume 6 | Issue 9 | e24296